Sebella Miller
About Sebella Miller
Sebella Miller is the Head of Clinical Operations - USA (Snr. Director) at Bristol Myers Squibb, with over three decades of experience in the pharmaceutical industry.
Company
Sebella Miller currently works at Bristol Myers Squibb as the Head of Clinical Operations - USA (Senior Director). The company is based in New Jersey, United States, and is well-known in the pharmaceutical industry for its commitment to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.
Title
Sebella Miller holds the position of Head of Clinical Operations - USA (Senior Director) at Bristol Myers Squibb. In this role, she is responsible for overseeing the clinical operations within the United States, ensuring that clinical trials and research meet regulatory and scientific standards.
Education and Expertise
Sebella Miller has over three decades of experience in the pharmaceutical industry, bringing substantial expertise in clinical research across multiple phases (I-IV). She began her career in clinical research in 1990 and has held positions at several major pharmaceutical companies, gaining thorough knowledge in the field.
Professional Background
Sebella Miller’s professional journey in clinical research started in 1990 at Hoechst Marion Roussel Ltd, where she worked as a Clinical Team Leader/CRA for 8 years. She then spent time at DuPont Pharmaceuticals as a CRA from 1999 to 2001. Following this, Sebella worked at Chiltern as a CRA phase I-IV, from 1999 to 2004. In 2004, she joined Johnson & Johnson UK as a CRA phase 1 for 11 months before transferring to the USA. For the past 18 years, she has been leading Clinical Operations at Bristol Myers Squibb.
Industry Experience
With extensive experience in the pharmaceutical industry spanning over 30 years, Sebella Miller has worked in various capacities across different regions, including the UK and the USA. Her roles have involved clinical research across all phases of clinical trials, from early phase I trials through to phase IV post-marketing studies. She has led teams and operations at multiple esteemed companies, honing her expertise and contributing significantly to the field of clinical research.